BeOne Medicines (BEIGF) Finished Goods (2017 - 2026)

BeOne Medicines (BEIGF) has 5 years of Finished Goods data on file, last reported at $298.2 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $298.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $298.2 million (changed N/A YoY), and the FY2025 annual result was $249.4 million, down 5.65% from the prior year.
• Finished Goods grew to $298.2 million in Q1 2026 per BEIGF's latest filing, from $249.4 million in the prior quarter.
• Over five years, Finished Goods peaked at $298.2 million in Q1 2026 and troughed at $249.4 million in Q4 2025.
• A 3-year average of $270.6 million and a median of $264.3 million in 2024 frame the typical range for Finished Goods.
• On a YoY basis, Finished Goods climbed as much as 5.65% in 2025 and fell as far as 5.65% in 2025.
• A 3-year view of Finished Goods shows it stood at $264.3 million in 2024, then slipped by 5.65% to $249.4 million in 2025, then advanced by 19.57% to $298.2 million in 2026.
• Business Quant data shows BEIGF's Finished Goods at $298.2 million in Q1 2026, $249.4 million in Q4 2025, and $264.3 million in Q4 2024.